Medical studies clarify benefits of cholesterol treatments for seniors and high-risk patients

Recent medical findings provide clearer insights into cholesterol management for older adults and high-risk patients. The STAREE study, published in the New England Journal of Medicine, investigated the efficacy of statins for primary prevention in individuals aged 70 and older who have no prior history of cardiovascular disease, diabetes, or dementia.

The study, which followed nearly 10,000 participants for a median of 5.9 years, found that daily atorvastatin (40 mg) reduced major cardiovascular events—including heart attack, stroke, and the need for revascularization—by approximately 30% compared to a placebo. In absolute terms, this represented a reduction of about 2 to 3 events per 100 people treated over six years. The study noted no demonstrated benefits regarding mortality, dementia, or disability.

Additionally, research into PCSK9 inhibitors, such as evolocumab and alirocumab, highlights their role in treating severe hypercholesterolemia. Unlike statins, which inhibit cholesterol synthesis, PCSK9 inhibitors work by blocking a protein produced by the liver, thereby increasing the liver's ability to remove LDL cholesterol from the bloodstream. These treatments are particularly relevant for patients who cannot reach therapeutic targets through statins alone.